Alkem Laboratories Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/e4aymsuwl0iast287alrxt8x.pdf

Key Takeaways


India Business: Chronic Outperformance, Trade Generics Reset

Amrut Naik: "I do not think the fundamentals of the business are different. Obviously, the dynamics in India is different, and I do think that we have a great team here... the market-beating growth that we have committed to the investor community, I think that we will continue to demonstrate that in India."

U.S. Business: Price Erosion Concentrated, Approvals Frozen

Sandeep Singh: "I know we look at Lupin's, and we all get excited, Lupin's numbers, but it is not going to be close to that. Let us give it a quarter to see how it is. But right now, we are not anywhere close to having a very meaningful contribution."

Enzene: Strategic Reset from Biosimilars to CDMO

Sandeep Singh: "Enzene, as we go forward, will be a more CDMO rather than a biosimilar play. Therefore, I think the biosimilar pipeline will not be that important for Enzene... it is a different business than the Alkem parent's business, so we will have to use a different lens."

MedTech & International Markets: Occlutech Consolidation, LATAM Momentum


Margins: Guidance Held Despite a Strong First Half

Sandeep Singh: "I would rather trade growth for breaking even."

Regulatory & Cost Watchpoints


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin20%-21% for FY27; not revised despite H1 outperformanceFY27 full year
Core pharma margin improvement100 bps YoY on reported margins, subject to geopolitics and MIP impactFY27
Structural margin expansion50 bps+ improvement every year from FY28 onwardStarting FY28
India revenue growthClose to 11% overall growthFY27 full year
U.S. revenue growthMid-single-digit constant-currency growth; H2 slightly better than H1FY27 full year
Non-U.S. international growthStrong double-digit H2; full-year weighted average mid-to-high teensFY27 full year
Enzene EBITDA breakevenBreakeven in 1.5-2 years maximumBy FY29
Enzene revenueRoughly double in sizeIn four years
MedTech EBITDA drag exitCome out of EBITDA dragIn one year
MedTech revenue3x current sizeIn five to six years
R&D spend4%-4.5% of revenueFY27
Enzene capexINR 300-350 crore, largely doneOver next three years
MedTech capexClose to INR 400 croreOver next three to four years
Daman product launches~8 products filed from Daman due for launch, contingent on FDA re-auditNext 6-12 months
Tolvaptan contributionNot expected to be meaningfulNext two quarters

Key Metrics

MetricQ2 FY27
Revenue from operations₹4,520 cr, +13.8% YoY
EBITDA₹1,025 cr, +11.3% YoY
EBITDA margin22.5%, vs 20.4% in FY26; Occlutech diluted margin by 80 bps this quarter
Core pharmaceutical EBITDA margin~26% in Q2, noted as seasonally high
R&D expenses4.3% of revenue; full-year guidance 4%–4.5%
Profit before tax+7.7% YoY
Net profit-11.7% YoY
Net cash₹4,900 cr+
India business IQVIA growth13.8% YoY, at par with IPM
Acute segment growth12.1% YoY, vs IPM 12.3%
Chronic segment growth22.4% YoY, vs IPM 16%, 640 bps outperformance
International business growth22.3% YoY
U.S. business growth2% YoY in reported terms; -3% in constant currency; volume +10%, price erosion ~16%
Non-U.S. business growth58% YoY; ex-Occlutech H1 growth 31%, full-year expected mid-teens to higher teens
Biotech (Enzene) sales₹70 cr, -35% YoY
MedTech sales₹133 cr, includes Occlutech consolidated from 16 July
India business full-year growth guidance~11%
U.S. business full-year growth guidanceMid-single digit in constant currency
FY27 EBITDA margin guidanceAt best on par with FY26 (~20.4%), possibly marginally lower
Pending ANDAs (U.S.)23 pending ANDAs, 18 tentative approvals; ~8 products from Daman due for launch in 6–12 months
Occlutech identifiable intangibles₹1,100 cr, amortized over 10 years; goodwill ₹700 cr
Occlutech PPA depreciation₹28 cr for the quarter, to continue in subsequent quarters
Enzene + MedTech combined capex₹600–700 cr over next 3–4 years
India chronic mix~24–25% of portfolio, vs industry ~65/35 acute/chronic